UCB appoints Jean-Christophe Tellier as chief executive

13 January 2015

Belgian drugmaker UCB has replaced chief executive Roch Doliveux with Jean-Christophe Tellier.

Mr Tellier will also be chairman of the executive committee and a member of the board of directors. His predecessor, Roch Doliveux, stepped down on December 31 2014 after a 10-year tenure.

Since joining the company in 2011, Mr Tellier has played a key role in driving the growth of UCB’s three core products, Cimzia (certolizumab pegol), Vimpat (lacosamide) and Neupro (rotigotine). He brings 25 years of experience in pharma to the role.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK